Neurocrine Biosciences (NBIX) FCF Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1,461.00 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -2,596.00 |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 874.00 |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 982.00 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 1,832.00 |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 1,733.00 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -176.00 |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 1,592.00 |
| 10 | Neurocrine Biosciences | 15.81 Bn | 15.42 Bn | 935.80 Mn | -2,476.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,476.00 |
| Mar 31, 2026 | 4,859.00 |
| Dec 31, 2025 | 1,424.00 |
| Sep 30, 2025 | 105.00 |
| Jun 30, 2025 | -2,117.00 |
| Mar 31, 2025 | 2,493.00 |
| Dec 31, 2024 | 3,898.00 |
| Sep 30, 2024 | 514.00 |
| Jun 30, 2024 | -2,525.00 |
| Mar 31, 2024 | -1,188.00 |
| Dec 31, 2023 | -1,338.00 |
| Sep 30, 2023 | 4,902.00 |
| Jun 30, 2023 | 41.00 |
| Mar 31, 2023 | -4,623.00 |
| Dec 31, 2022 | -452.00 |
| Sep 30, 2022 | -1,655.00 |
| Jun 30, 2022 | 165.00 |
| Mar 31, 2022 | 6,862.00 |
| Dec 31, 2021 | -3,534.00 |
| Sep 30, 2021 | -1,832.00 |